Folic Acid Should Begin Before Conception, Not After the Positive Test
Folic acid remains one of the clearest examples of preventive medicine working exactly where biology demands it: before a defect can form. Neural tube closure occurs very early in embryogenesis, typically by 26 to 28 days after fertilization, long before many patients realize they are pregnant. By that point, the window for preventing neural tube defects has largely passed.
For that reason, supplementation should start before conception, ideally at least one month in advance, and continue through the first 12 weeks of pregnancy. The US Preventive Services Task Force recommends 400 to 800 micrograms of folic acid daily for anyone who is planning pregnancy or could become pregnant, beginning at least one month before conception and continuing through the first two to three months of pregnancy. ACOG recommends a prenatal vitamin containing at least 400 micrograms beginning at least one month before pregnancy and continuing through the first 12 weeks, while the CDC advises 400 micrograms daily for all women capable of becoming pregnant.
The clinical logic is straightforward. Half of pregnancies are unplanned, so a strategy tied only to active family planning misses many patients during the exact weeks when neural tube closure is underway. Food fortification has helped, but it has not replaced supplementation. An analysis cited by the USPSTF found that only about half of women of reproductive age obtained the recommended amount from fortified foods alone, and supplemental folic acid has greater bioavailability than naturally occurring food folate.
When pregnancy occurs unexpectedly, the correct response is not to abandon supplementation because the earliest embryologic steps have already begun. Folic acid should be started as soon as pregnancy is recognized and continued through the recommended early gestational period. The preventive effect on neural tube defects is strongest around conception, but the practical message for clinicians is broader: the prescription belongs in preconception care, not in a reactionary prenatal visit after weeks of development have already elapsed.
Women with a prior pregnancy affected by a neural tube defect require a separate approach. They are generally advised to take 4 mg per day, beginning before conception and continuing through the first trimester, with ACOG recommending that this higher dose start at least three months before pregnancy. That dose escalation reflects the elevated recurrence risk in a population with a documented prior affected pregnancy.
Why Folic Acid Matters Beyond Neural Tube Closure
The strongest evidence for folic acid remains prevention of spina bifida and anencephaly. Randomized trials and systematic reviews have consistently supported this effect, making folate supplementation one of the best-established interventions in prenatal care.
The biology is also compelling. Folate participates in one-carbon metabolism, nucleotide synthesis, and DNA methylation, all of which are central to rapidly dividing fetal tissue. Those same pathways help explain why investigators have asked whether folate exposure may influence not only structural development but also later neurodevelopment.
Observational data point in that direction, though they do not settle the question. In the Norwegian Mother and Child Cohort Study, folic acid use from four weeks before conception through eight weeks after conception was associated with a lower risk of autistic disorder in children, with an adjusted odds ratio of 0.61. Levine and colleagues reported lower likelihood of autism spectrum disorder in offspring when folic acid and/or multivitamin use occurred before pregnancy and during pregnancy. A 2021 meta-analysis of 10 studies, including nearly 9,800 autism cases, found that early pregnancy folic acid supplementation was associated with a lower risk of autism spectrum disorder, with an odds ratio of 0.57.
These studies are not randomized trials, and that matters because supplement users and nonusers often differ in ways that are difficult to fully adjust for. Health behaviors, pregnancy planning, diet quality, socioeconomic position, and access to care can all shape both supplement use and child outcomes. A large prospective cohort study from Japan did not find a significant association between folic acid supplementation before or during pregnancy and autism spectrum disorder, and a 2025 umbrella review concluded that folic acid may reduce the risk of autism, ADHD, and behavioral problems while emphasizing that much of the evidence is low quality and observational.
The evidence supporting neural tube defect prevention is strong; the evidence for protection against autism or related neurodevelopmental disorders is promising but still preliminary.
The FASSTT Trial Raised a New Question About Later Pregnancy Exposure
One of the more intriguing findings in this area comes from the Folic Acid Supplementation in the Second and Third Trimesters trial, or FASSTT, which evaluated whether continuing 400 micrograms of folic acid through the second and third trimesters affected child cognition. In this randomized controlled trial from Ireland, 119 mother-child pairs were enrolled, with 70 children assessed at age 7 years and 39 at age 3 years.
The results were modest in size but clinically provocative. At age 7, children whose mothers received folic acid scored higher than those in the placebo group on word reasoning, with mean scores of 13.3 versus 11.9. At age 3, children in the folic acid group also had higher cognitive scores than those in the placebo group, 10.3 versus 9.5. The trial also compared the children’s age-7 scores with a nationally representative British sample. Children exposed to folic acid had higher scores than the national sample on verbal IQ, performance IQ, general language, and full-scale IQ, while children in the placebo group differed from the national sample on fewer measures.
These findings do not establish a new standard of care, but they do make biological sense. The fetal brain remains highly active well beyond the first trimester, and folate-dependent methylation and nucleotide synthesis continue to support neurodevelopment during later gestation. A supplementation strategy that protects early embryologic closure may also influence later neuronal growth, connectivity, and myelination, though that mechanism remains inferential rather than proven by the trial.
Small trial, real signal.
The study’s size limits confidence, and the follow-up sample was smaller still. Even so, the randomized placebo-controlled design gives the FASSTT data a credibility that observational studies cannot match. It suggests that continued folate exposure during pregnancy may merit more study, especially because the standard prenatal vitamin dose is already widely used and has a strong safety record.
What Clinicians Can Say Today
The practical message for care is settled on one point and still open on another. Start folic acid before conception when possible, continue through early pregnancy, and do not stop simply because the first trimester has passed. There is no recommendation to discontinue folic acid after the first trimester, and the current prenatal dosing range has a long safety history.
What remains unanswered is whether routine continuation through the second and third trimesters should be promoted specifically for child neurodevelopment. The FASSTT trial suggests the possibility, but the total evidence base is too limited to convert that signal into a universal recommendation. For now, continuing a prenatal vitamin through pregnancy is entirely reasonable, especially because the supplement is already indicated for maternal nutritional support and because the available data do not suggest harm at recommended doses.
The unresolved clinical question is not whether folic acid works at the beginning of pregnancy. It does. The question is whether sustained exposure later in gestation meaningfully improves cognitive outcomes in offspring, and that answer still depends on larger, better-powered trials with longer follow-up.